Multiple clinical data for advanced solid tumors of Maiwei Biotech’s “9MW2821” will be announced soon

Introduction: 9MW2821 is Maiwei Biotech’s first site-specific conjugated ADC drug targeting nectin-4.

Maiwei Bio announced that it will announce the use of the innovative drug 9MW2821 targeting Nectin-4 in the form of an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO) to be held in Chicago, USA, from May 31 to June 4, 2024 local time. Results of phase I/II clinical studies on multiple advanced solid tumors.

Oral report

Abstract title: 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.

Reporting time: June 3, 2024, 8:00-9:30 a.m. Central Time

Speaker: Professor Zhang Jian/Chief Physician/PhD Supervisor (Fudan University Cancer Hospital)

Abstract Number: 3013

About 9MW2821

9MW2821 is Maiwei Biotech’s first site-conjugated ADC new drug targeting Nectin-4. It is an innovative product developed by the company using two platform technologies: ADC drug development platform and automated high-throughput hybridoma antibody molecule discovery platform. It is an innovative product jointly developed by domestic enterprises. It is the first variety of target drugs to carry out clinical trials. 9MW2821 has carried out multiple clinical studies in China to evaluate its safety, tolerability, pharmacokinetic characteristics and therapeutic effect in patients with various advanced solid tumors.

The Phase III clinical study of 9MW2821 as a monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma treated with platinum-based chemotherapy and PD-(L)1 inhibitors has been officially launched, and the Phase I/II study of 9MW2821 in combination with PD-1 inhibitors has been officially launched. Clinical studies are also progressing, and the first subjects have been enrolled. In February 2024, it was granted “Fast Track Designation” (FTD) by the FDA for the treatment of advanced, recurrent or metastatic esophageal squamous cell carcinoma. It is currently the world’s first Nectin-4-targeting therapeutic drug to disclose clinical effectiveness and safety data for esophageal cancer and cervical cancer indications.